Treatment of lung adenocarcinomas (LUAD) that exhibit activated epidermal growth factor receptor (EGFR) with EGFR tyrosine kinase inhibitors (TKI) has limited efficacy. Assessment of the impact of EGFR TKI on the LUAD surfaceome remodeling revealed potential therapeutic targets. We identified placen...
ORGANISM(S): Homo sapiens (Human)